IP Library › Granted Patent US 12,527,772
Granted Patent B2
US 12,527,772 · App. 18/341,853 · Granted Jan 20, 2026

Pharmaceutical combination comprising ponesimod

Inventors: Martine Clozel (Allschwil, CH); Laetitia Pouzol (Allschwil, CH)
Assignee: Vanda Pharmaceuticals Inc.
A61K31/426A61K31/167A61K31/421A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,527,772
App. No.
18/341,853
Granted
Jan 20, 2026
Kind
B2
Abstract

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.

Claims (14)

1 . A method for treating a disease or disorder associated with a lymphocyte-mediated activated immune system in a human subject in need thereof, comprising

administering to the subject a pharmaceutically effective amount of a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is teriflunomide,

wherein the first active ingredient and the second active ingredient are in synergistically effective amounts for treating the disease or disorder associated with a lymphocyte-mediated activated immune system;

wherein the synergistically effective amount of the first active ingredient is less than 20 mg and the synergistically effective amount of the second active ingredient is less than 14 mg; and

wherein the disease or disorder associated with a lymphocyte-mediated activated immune system is autoimmune syndromes selected from the group consisting of rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, and Hashimoto's thyroiditis; or atopic dermatitis.

2 . The method according to claim 1 , wherein the first and the second active ingredient are contained in a single pharmaceutical composition.

3 . The method according to claim 1 , wherein the first and the second active ingredient are contained in separated pharmaceutical compositions.

4 . The method according to claim 1 , wherein the pharmaceutical combination further comprises at least one therapeutically inert excipient.

5 . The method according to claim 1 , wherein the pharmaceutical combination further comprises at least two therapeutically inert excipients.

6 . The method according to claim 1 , wherein the autoimmune syndrome is rheumatoid arthritis.

7 . The method according to claim 1 , wherein the autoimmune syndrome is psoriasis.

8 . The method according to claim 1 , wherein the autoimmune syndrome is psoriatic arthritis.

9 . The method according to claim 1 , wherein the autoimmune syndrome is Crohn's disease.

10 . The method according to claim 1 , wherein the autoimmune syndrome is Hashimoto's thyroiditis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2024
From: ACTELION PHARMACEUTICALS LTD
To: VANDA PHARMACEUTICALS INC.
Reel/Frame 066276/0577 →
Priority Claims (1)
WO PCT/EP2017/055994 · Mar 14, 2017 · international
Continuity (2)
Continuation 16494163
Related Publication 20240139161A1 · May 2, 2024
References Cited (63)
US 4087535A · Heubach · 1978 [cited by applicant]
US 4284786A · Kaemmerer et al. · 1981 [cited by applicant]
US 4965276A · Bartlett et al. · 1990 [cited by applicant]
US 5459163A · Bartlett et al. · 1995 [cited by applicant]
US 5679709A · Bartlett et al. · 1997 [cited by applicant]
US 6894184B2 · Hachtel et al. · 2005 [cited by applicant]
US 8263780B2 · Abele et al. · 2012 [cited by applicant]
US 8273779B2 · Binkert et al. · 2012 [cited by applicant]
US RE43728E · Binkert et al. · 2012 [cited by applicant]
US RE43833E · Binkert et al. · 2012 [cited by applicant]
US 8785484B2 · Brossard et al. · 2014 [cited by applicant]
US RE45174E · Binkert et al. · 2014 [cited by applicant]
US 8912340B2 · Abele et al. · 2014 [cited by applicant]
US 9062014B2 · Bonham et al. · 2015 [cited by applicant]
US 9340518B2 · Herse · 2016 [cited by applicant]
US 10220023B2 · Dingemanse et al. · 2019 [cited by applicant]
US 10245253B2 · Clozel et al. · 2019 [cited by applicant]
US 10251867B2 · Brossard et al. · 2019 [cited by applicant]
US 20020177623A1 · Wettstein · 2002 [cited by applicant]
US 20120039866A1 · Salvemini · 2012 [cited by applicant]
US 20140316140A1 · Brossard et al. · 2014 [cited by applicant]
US 20190091190A1 · Terwey et al. · 2019 [cited by applicant]
CN 104684553A · 2015 [cited by applicant]
EP 1381356B1 · 2008 [cited by applicant]
WO 0160363A1 · 2001 [cited by applicant]
WO 2002080897A1 · 2002 [cited by applicant]
WO 2005054215A1 · 2005 [cited by applicant]
WO 2006044741A1 · 2006 [cited by applicant]
WO 2007118684A1 · 2007 [cited by applicant]
WO 2008062376A2 · 2008 [cited by applicant]
WO 2009115954A1 · 2009 [cited by applicant]
WO 2010046835A1 · 2010 [cited by applicant]
WO 2011032929A1 · 2011 [cited by applicant]
WO 2012018704A1 · 2012 [cited by applicant]
WO 2014020156A1 · 2014 [cited by applicant]
WO 2014027330A1 · 2014 [cited by applicant]
WO 2016079687A1 · 2016 [cited by applicant]
WO 2016091996A1 · 2016 [cited by applicant]
WO 2016092042A1 · 2016 [cited by applicant]
WO 2016205654A1 · 2016 [cited by applicant]
Aubagio (teriflunomide) Tablets, for oral use, “Highlights of Prescribing Information,” 2022, pp. 1-8. [cited by applicant]
Balabanova et al., “Leflunomide (Arava) in Early Rheumatoid Arthritis,” 43 (5) Scientific and Practical Rheumatology 2005, vol. 3. [cited by applicant]
Bate et al., “A Common Control Group—Optimising the Experiment Design to Maximise Sensitivity,” PLoS One, 2004, vol. 9, No. 12, e114872, pp. 1-12. [cited by applicant]
D'Ambrosio, “Ponesimod, A Selective S1P1 Receptor Modulator: A Potential Treatment for Multiple Sclerosis and Other Immune-Mediated Diseases”, Ther Adv Chronic Dis, 2016, vol. 7, No. 1, pp. 18-33. [cited by applicant]
Dominican Republic Office Action dated Oct. 26, 2021, issued by the Dominican Republic Patent Office in Applicant's corresponding Dominican Republic Appl. No. P2019-0257, and the English translation, 6 pages. [cited by applicant]
Ellwardt et al., “Molecular Mechanisms Linking Neuroinflammation and Neurodegeneration in MS”, Experimental Neurology, 2014, vol. 262, pp. 8-17. [cited by applicant]
George, “Ponesimod Bests Aubagio in Head-to-Head MS Trial: Investigational Drug Reduces Annual Relapse Rate, Shows Effects on Fatigue,” MedPage Today, 3 pages, Webpage https://www.medpagetoday.com/meetingcoverage/ectrim… [cited by applicant]
Gold et al., “Pathophysiology of Multiple Sclerosis and the Place of Teriflunomide,” Acta Neurol Scand, 2011, vol. 124, pp. 75-84. [cited by applicant]
Kappos et al., “Ponesimod Compared with Teriflunomide in Patients with Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 Optimum Study: A Randomized Clinical Trial,” JAMA Neurology, 2021, vol. 78, No. 5, pp.… [cited by applicant]
Long-Term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of 20 mg Ponesimod in Patients with Relapsing Multiple Sclerosis (Optimum-LT), Webpage <https://clinicaltrails.gov/ct2/show… [cited by applicant]
Oh et al., “Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects”, Ther Adv Neurol Disord., 2014, vol. 7, No. 5, pp. 239-252. [cited by applicant]
Olsson, “Oral Ponesimod in Relapsing-Remitting Multiple Sclerosis: A Randomised Phase II Trial”, J Neurol Neurosurg Psychiatry, 2014, vol. 85, pp. 1198-1208. [cited by applicant]
Oral Ponesimod Versus Teriflunomide in Relapsing Multiple Sclerosis (Optimum), Clinical Trial Identifier: NCT02425644, 8 pages, Webpage https://clinicaltrails.gov/ct2/show/NCT02425644 published on Apr. 24, 2015 and retr… [cited by applicant]
Piali et al., “The Selective Sphingosine I-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation,” The Journal of Pharmacology and Experimental Therapeutics, vol. 337, No. 2, pp… [cited by applicant]
Pouzol et al., “Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis,” Innov Clin Neurosci. 2019, vol. 16, No. 3-4, pp. 22-30. [cited by applicant]
Remington, “Pharmaceutical Manufacturing,” The Science and Practice of Pharmacy, 21st Edition, Part 5, 2005. [cited by applicant]
Stahl et al., “Handbook of Pharmaceutical Salts: Properties Selection, and Use,” Wiley-VCH, 2008, pp. 329-350. [cited by applicant]
Switching Disease Modifying Therapies in Multiple Sclerosis, Cleveland Clinic, Neurological Institute Menu, 13 pages, 2020, retrieved from The Wayback Machine on Aug. 9, 2022. <https://web.archive.org/web/20200805165754… [cited by applicant]
Therapeutic Positioning Report PT-Teriflunomide/VI/220415, Ministry of Health, Spain, 5 pages, 2015; No English translation. [cited by applicant]
Ukrainian Office Action dated Sep. 14, 2021, issued by the Ukrainian Patent Office in Applicant's corresponding Ukrainian Appl. No. 20093/3A/21, and the English translation, 8 pages. [cited by applicant]
Vaclavkova et al., “Oral Ponesimod in Patients with Chronic Plaque Psoriasis: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial,” The Lancet, 2014, vol. 384, No. 9959, pp. 1-14 pages; Abstract Only. [cited by applicant]
Weaver et al., “An Elevated Matrix Metalloproteinase (MMP) in an Animal Model of Multiple Sclerosis is Protective by Affecting Th1/Th2 Polarization,” FASEB J., 2005, vol. 19, No. 12, pp. 1-21. [cited by applicant]
Wouters et al., “Pharmaceutical Salts and Co-crystals,” RSC Publishing, 2012, pp. 1-10. [cited by applicant]